Tag: pegbelfermin

Non-alcoholic steatohepatitis (NASH), the most common chronic liver disease in the United States, puts patients at increased risk of developing cirrhosis and hepatocellular carcinoma. Patients with NASH are also at an increased risk of experiencing cardiovascular events and overall mortality. Pegbelfermin (BMS-986036) is a PEGylated human fibroblast growth factor...
Pegbelfermin (BMS-986036), a PEGylated Fibroblast Growth Factor 21 Analogue, in Patients with Non-Alcoholic Steatohepatitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2a Trial Non-alcoholic steatohepatitis (NASH), the most common chronic liver disease in the United States, puts patients at increased risk of developing cirrhosis and hepatocellular carcinoma. Patients with NASH are also...